Crizotinib was approved for metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in 2011 and metastatic ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)-rearranged NSCLC in 2016 [70]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.